Skip to content

Research at St Andrews

Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

Research output: Contribution to journalArticle

Author(s)

Alexander L. R. Lubbock, Grant D. Stewart, Fiach C. O'Mahoney, Alexander Laird, Peter Mullen, Marie O'Donnell, Thomas Powles, David J. Harrison, Ian M. Overton

School/Research organisations

Abstract

Background: Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification.
Methods: We investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint.
Results: The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 × 10−7; hazard ratio (HR) 37.9, 95% confidence interval 4.1–353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044).
Conclusions:  This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods.
Close

Details

Original languageEnglish
Article number118
Number of pages12
JournalBMC Medicine
Volume15
DOIs
StatePublished - 26 Jun 2017

    Research areas

  • Cancer, Tumour heterogeneity, Prognostic markers, Renal cell carcinoma, Tumour biomarkers

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT

    Brown, J. L., Shovman, M., Robertson, P., Boiko, A., Goltsov, A., Mullen, P. & Harrison, D. J. May 2017 In : Oncotarget. 8, 18, p. 29657-29667 11 p.

    Research output: Contribution to journalArticle

  2. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

    Meehan, J., Ward, C., Turnbull, A., Bukowski-Wills, J., Finch, A., Jarman, E. J., Xintaropoulou, C., Martinez-Perez, C., Gray, M., Pearson, M., Mullen, P., Supuran, C. T., Carta, F., Harrison, D. J., Kunkler, I. H. & Langdon, S. 2017 In : Oncotarget. 8, 26, p. 42857-42875

    Research output: Contribution to journalArticle

  3. Total synthesis of dehaloperophoramidine using a highly diastereoselective Hosomi-Sakurai reaction

    Wilkie, R. P., Neal, A., Johnston, C. A., Voûte, N., Lancefield, C. S., Stell, M., Medda, F., Makiyi, E. F., Turner, E., Ojo, O. S., Slawin, A. M. Z., Lebl, T., Mullen, P., Harrison, D. J., Ireland, C. M. & Westwood, N. J. 14 Sep 2016 In : Chemical Communications. 52, 71, p. 10747-10750

    Research output: Contribution to journalArticle

  4. Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models

    Martínez-Pérez, C., Ward, C., Turnbull, A. K., Mullen, P., Cook, G., Meehan, J., Jarman, E. J., Thomson, P. I. T., Campbell, C. J., McPhail, D., Harrison, D. J. & Langdon, S. P. 13 Apr 2016 In : British Journal of Cancer. 114, 8, p. 905-916

    Research output: Contribution to journalArticle

  5. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer

    Huang, R., Langdon, S. P., Tse, M., Mullen, P., Um, I. H., Faratian, D. & Harrison, D. J. 14 Dec 2015 In : Oncotarget. 7, 4, p. 4695-4711 17 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

    Murphy, M. E., Wills, G. H., Murthy, S., Louw, C., Bateson, A. L. C., Hunt, R. D., McHugh, T. D., Nunn, A. J., Meredith, S. K., Mendel, C. M., Spigelman, M., Crook, A. M., Gillespie, S. H. & REMoxTB Consortium 17 Oct 2018 In : BMC Medicine. 16, 11 p., 189

    Research output: Contribution to journalArticle

  2. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Wills, G. H., Crook, A. M., Dawson, R., Diacon, A. H., Louw, C. E., McHugh, T. D., Mendel, C., Meredith, S., Mohapi, L., Murphy, M. E., Murray, S., Murthy, S., Nunn, A. J., Phillips, P. P. J., Singh, K., Spigelman, M. & Gillespie, S. H. 28 Mar 2018 In : BMC Medicine. 16, 10 p., 46

    Research output: Contribution to journalArticle

  3. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis

    Murthy, S. E., Chatterjee, F., Crook, A., Dawson, R., Mendel, C., Murphy, M. E., Murray, S. R., Nunn, A. J., Phillips, P. P. J., Singh, K. P., McHugh, T. D., Gillespie, S. H. & REMoxTB Consortium 21 May 2018 In : BMC Medicine. 16, 11 p., 73

    Research output: Contribution to journalArticle

  4. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

    Phillips, P. P. J., Mendel, C. M., Nunn, A. J., McHugh, T. D., Crook, A. M., Hunt, R., Bateson, A. & Gillespie, S. H. 24 Nov 2017 In : BMC Medicine. 15, 9 p., 207

    Research output: Contribution to journalArticle

ID: 250007022